|| Checking for direct PDF access through Ovid
Respiratory virus infections are the single greatest precipitants of asthma exacerbations.Current treatment options for AE are limited and have developed little in recent years.Development of effective anti-viral treatments remains a key target for therapeutic intervention.Approaches include therapies that either target the virus or boost host response to the virus.New clinical studies are needed to further our understanding of the mechanisms of virus induced asthma exacerbation.Asthma is the most common chronic respiratory disease and its prevalence is on the increase. Respiratory viral infections in early life have been suggested to increase the risk of development of asthma in later life and virus infection remains the single greatest precipitant of asthma exacerbations. The development of effective anti-viral treatments remains a key target for therapeutic intervention. Here we discuss the role of respiratory viral infection in asthma exacerbation and highlight current and potential anti-viral agents and their mechanisms of action.